enGene Holdings Inc.

NASDAQ:ENGN

Biotechnology

Healthcare
$1.85 -1.15%

-$0.02 today

Market cap
$123.98M
Beta
-0.29
P/E (TTM)
-1.8
EPS (TTM)
-$0.95
52W Low $1.40High $12.25

Volume 2.81M

Average 1.58M

ENGN Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

enGene Holdings Inc.NASDAQ: ENGN

Research & Development · Q2 FY2026 · quarter ended Apr 2026

Research & development grows, but more slowly than its trailing trend

Q2 FY2026 research & development of $22.2M rose 9.8% year over year, behind the +56.7% change in trailing-twelve-month research & development. Sequentially, it fell 0.3% from the prior quarter. Over 3 fiscal years it compounded at +82.8% a year.

Context

  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +9.8% toward the trailing-twelve-month pace of +56.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterApr 2026
$22.2M-0.3% QoQ
Last fiscal yearOct 2025
$94.48M+146.6% YoY
LTMApr 2026
$98.75M+56.7% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+9.8%——
1 year+146.6%——
3-year CAGR+82.8%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
94.48M USD
Year-over-year change
+146.6%
4-year CAGR
+65.9%

Research & Development vs competitors

How ENGN compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +56.7% is the 2nd highest of 10, against a peer median of +5.0%.
  • Over three fiscal years its annual growth of +82.8% compares with a peer median of +15.7%.
ENGN Competitors
Research & Development for ENGN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANNXAnnexon, Inc.LTM Mar 2026$172.31M USD+17.5%+18.0%—
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$152.7M USD+75.7%+85.3%—
DBVTDBV Technologies S.A.LTM Mar 2026$124.71M USD+42.2%+15.6%—
ENGNenGene Holdings Inc.LTM Apr 2026$98.75M USD+56.7%+82.8%—
CLLSCellectis S.A.LTM Mar 2026$94.68M USD+5.0%-1.4%139.0%
ALTAltimmune, Inc.LTM Mar 2026$66.77M USD-12.8%-2.0%185483.3%
SLNSilence Therapeutics plcLTM Mar 2026$61.84M USD—+24.0%6710.8%
KRROKorro Bio, Inc.LTM Mar 2026$58.79M USD-15.8%+15.8%1530.1%
ANROAlto Neuroscience, Inc.LTM Mar 2026$55.94M USD+19.0%+24.4%—
ACIUAC Immune S.A.LTM Mar 2026CHF 52.18M CHF-17.6%-2.2%1409.6%
AMRNAmarin Corporation plcLTM Mar 2026$18.45M USD-6.9%-13.3%8.6%
Peer median (excluding ENGN) —+5.0%+15.7%1469.9%

Competitors are the stored peer set for ENGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Oct 2021
FY2022
Oct 2022
FY2023
Oct 2023
FY2024
Oct 2024
FY2025
Oct 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development12.46M15.47M16.46M38.32M94.48M
Selling, General & Admin3.16M3.26M8.47M23.98M28.69M
Operating Expenses15.87M19.43M26.06M62.3M123.17M
Depreciation & Amortization272K238K175K323K509K
EBITDA(18.15M)(22.78M)(94.77M)(52.04M)(113.8M)
EBITDA Margin—————
Operating Income(15.87M)(19.43M)(26.06M)(62.3M)(123.17M)
Operating Margin—————
Interest Income25K129K1.12M10.41M9.43M
Interest Expense5.02M1.42M4.95M2.8M2.99M
Other Income / Expenses(7.57M)(5.01M)(73.84M)7.14M5.86M
Income Before Tax(23.44M)(24.44M)(99.9M)(55.16M)(117.3M)
Pre-Tax Margin—————
Income Tax Expense022K17K(19K)0
Net Income(23.44M)(24.46M)(99.92M)(55.14M)(117.3M)
Net Margin—————
EPS (Basic)(0.01)0.00(4.24)(1.46)(2.29)
EPS (Diluted)(0.01)0.00(4.24)(1.46)(2.29)
Weighted Avg Shares15.81M15.81M23.56M44.64M51.12M
Weighted Avg Shares (Diluted)15.81M15.81M23.56M44.64M51.12M

enGene Holdings Inc.

NASDAQ:ENGN

Intrinsic Alpha fair value

Locked

Current Price

$1.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.